Meeting
2019 Genitourinary Cancers Symposium
Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.
Authors
Julio Chong
Icahn School of Medicine at Mount Sinai, New York, NY
Julio Chong , Mitchel Muhleman , Rollin Say , Lale Kostakoglu , Jalal Ahmed , Ashutosh Tewari , Richard Stock , William K. Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 214)
DOI
10.1200/JCO.2019.37.7_suppl.214
Abstract #
214
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Impact of 18F-fluciclovine PET on salvage radiotherapy plans for men with post-radical prostatectomy recurrence of prostate cancer.
First Author: Heather Ann Payne
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.
First Author: Przemyslaw Twardowski
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient-reported outcomes of fully adaptive MR-guided stereotactic radiotherapy to prostate: Real-world experience from the UK.
First Author: Prantik Das
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang